Bridge Labs Awarded NIDA Tox Contract

Bridge Laboratories has been awarded a follow-on contract by the National Institute on Drug Abuse (NIDA). The five-year contract has an estimated value of $4.1 million if all options are exercised. Under the new contract, Bridge will provide toxicological evaluations for potential medications used to treat drug abuse.
   
“We appreciate the confidence NIDA has shown in Bridge Laboratories over the past five years and look forward to collaborating with them to find ways to significantly improve prevention, treatment, and policy as it relates to drug abuse and addiction,” said Tom Oakley, president and chief executive officer, Bridge Laboratories.